The CCR9 Knockout Jurkat Polyclonal Cells consist of a Jurkat T lymphocyte population with CRISPR/Cas9-mediated disruption of the CCR9 gene, yielding a heterogeneous polyclonal knockout pool. This format provides a genetically diverse loss-of-function model that avoids the selective pressures of single-cell cloning, making it suitable for functional studies of CCR9-dependent pathways in a cell line widely used for T cell research. The polyclonal nature preserves a spectrum of knockout efficiencies and minimizes clonal artifacts, offering a robust platform for chemokine receptor research and drug target validation.
The Jurkat host cell line originates from an acute T cell leukemia and represents an immortalized human T lymphocyte model. Jurkat cells are extensively employed to dissect T cell receptor signaling, cytokine responses, and signal transduction mechanisms due to their retention of critical T cell signaling machinery and ease of genetic manipulation. This background provides a relevant cellular context for examining the role of CCR9 in lymphocyte migration and function.
CCR9 is a chemokine receptor that selectively binds CCL25, transducing signals via G??i/o proteins. Ligand engagement stimulates PLC??-mediated calcium flux and activates MAPK/ERK and PI3K/Akt pathways, which regulate transcription factors such as NFAT and AP-1. This cascade promotes ??1 integrin activation and directed cell migration. Receptor sensitivity is modulated by GRK-mediated phosphorylation and ??-arrestin recruitment. Upstream regulators including IL-7, TGF-??, GATA3, and TCF-1 control CCR9 expression. Disruption of CCR9 eliminates these ligand-induced signals, enabling analysis of chemokine-driven T cell responses.
In Jurkat cells, CCR9 knockout ablates chemotactic responses to CCL25 and downstream signaling, offering a model to study T cell homing to intestinal and thymic sites. This is especially relevant for inflammatory bowel disease, celiac disease, and Crohn’s disease, where CCR9-mediated lymphocyte trafficking contributes to pathology. Additionally, the Jurkat T-ALL origin allows investigation of CCR9 in leukemia cell migration and survival.
These polyclonal knockout cells are suited for signaling studies via Western blotting and RT-qPCR, chemotaxis assays toward CCL25 gradients, and calcium flux measurements. Flow cytometry can confirm loss of surface CCR9, while phosphorylation analyses of ERK and Akt, and NFAT/AP-1 reporter assays, delineate downstream pathway activity. Co-immunoprecipitation experiments can probe receptor?CG protein interactions. The model enables drug sensitivity testing and migration/invasion assays for target validation in inflammation and cancer. For further information, please contact Ascent Research.
